leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...5859606162636465666768...235236»
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Short-course Radiotherapy (5 (clinicaltrials.gov) -  Feb 16, 2023   
    P1,  N=9, Recruiting, 
    N=160 --> 92 | Not yet recruiting --> Terminated; Production halt of FUDR in China Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: Jun 2021 --> Jun 2025
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion:  TRICE: Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (clinicaltrials.gov) -  Feb 15, 2023   
    P2,  N=176, Completed, 
    Trial completion date: Jun 2023 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2025 Recruiting --> Completed
  • ||||||||||  nisevokitug (NIS793) / Novartis
    Enrollment open, Combination therapy:  A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer (clinicaltrials.gov) -  Feb 14, 2023   
    P2,  N=45, Recruiting, 
    Lack of biochemical response to 2 months of 1L FFX may identify a subgroup of patients with a very high rate of response to 2L GnP, emphasizing the importance of assessing treatment response at 2-month intervals. Not yet recruiting --> Recruiting
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Discovery of novel MAP4K4/MLK3 dual inhibitor for pancreatic cancer (PDAC) (Hall F-H (Indiana Convention Center)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_12239;    
    PDAC standard-of-care chemotherapies include FOLFIRINOX, Gemcitabine, and Abraxane...The KRAS mutation is universal in PDAC, and recently a small molecule therapeutic, Sotorasib, targeting the KRAS G12C mutant protein was approved for non-small cell lung cancer (NSCLC) harboring the G12C mutation; however, only 50% of patients respond and the majority of patients develop resistance...Herein, we describe progress towards the development of MAP4K4/MLK3 dual inhibitor, DYMM-003 which represents an effective molecular probe to study the role of MAP4K4 and MLK3 and continued development for improved treatments of PDAC. The synthesis, binding assays, and inhibition assays for the new analogs will be presented.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
    Trial completion date, Trial initiation date, Trial primary completion date:  LOGICAN: Oxaliplatin  (clinicaltrials.gov) -  Feb 13, 2023   
    P2,  N=118, Recruiting, 
    The synthesis, binding assays, and inhibition assays for the new analogs will be presented. Trial completion date: Oct 2027 --> Jan 2027 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Oct 2026 --> Jan 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal:  Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy. (Pubmed Central) -  Feb 12, 2023   
    Surgery with lymphadenectomy, adjuvant therapy, and neoadjuvant therapy are thought to help improve survival outcomes. Modern treatment approaches for conventional pancreatic ductal adenocarcinoma could be applied to pancreatic carcinosarcoma.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Journal:  HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients. (Pubmed Central) -  Feb 12, 2023   
    Firstly, it evaluates the benefits and the added value of the introduction of trifluridine/tipiracil (FTD/TPI) in the Italian clinical practice, defining the comparative efficacy and safety profiles with respect to the other available treatment options (represented by the best supportive care (BSC) and FOLFIRI (5-FU, irinotecan, and leucovorin) regimens)...According to experts' opinions, lower perceptions of FTD/TPI emerged concerning equity aspects, whereas it would improve both individuals' and caregivers' quality of life. In conclusion, the results have demonstrated the strategic relevance related to the introduction of FTD/TPI regarding the coverage of an important unmet medical need of patients with metastatic gastric cancer who were refractory to at least two prior therapies, with important advantages for patients and hospitals, thus optimizing the clinical pathway of such frail patients.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer. (Pubmed Central) -  Feb 11, 2023   
    To the best of our knowledge, this regorafenib-induced severe proctitis secondary to radiation recall has not been reported in the literature before. No abstract available
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. (Pubmed Central) -  Feb 11, 2023   
    This triple combining regimen also leads to a significant decrease in Treg and MDSC and a significant increase in CD8?+?INF-??+?lymphocytes and M1/M2 macrophage ratio in the tumor microenvironment. Our study showed triple combining therapy with FOLFOX, CD47 and PD-L1 is an effective treatment regimen in CT-26 mice tumor model and may consider as a potential to translate to the clinic.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer (Pubmed Central) -  Feb 11, 2023   
    The 6 cases consisted of 3 patients in the third-line treatment, 1 patient in the fourth-line treatment, and 2 patients in the sixth-line treatment. The anti-tumor effect was PD in all cases in the third-line and fourth-line treatment, but the 2 patients of sixth-line treatment were controlled diseases.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Preclinical, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  HROP68: A rare case of medullary pancreatic cancer-characterization and chemosensitivity of the first patient-derived cell line. (Pubmed Central) -  Feb 10, 2023   
    This study illustrates the establishment of the first preclinical MPC models as well as the first in-depth characterization of an MPC PDCL. Since the scientific and clinical knowledge of this rare pancreatic cancer type is very limited, the presented models contribute to a better understanding of MPC and might be a valuable tool for the development of future treatment options.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    P1/2 data, Journal, Metastases:  Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma - a phase ib/ii study. (Pubmed Central) -  Feb 10, 2023   
    Since the scientific and clinical knowledge of this rare pancreatic cancer type is very limited, the presented models contribute to a better understanding of MPC and might be a valuable tool for the development of future treatment options. The addition of durvalumab to induction FOLFOX and PET directed CRT prior to surgery is safe, with a high rate of pathologic response, as well as encouraging survival data.